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Abstract: Nonalcoholic steatohepatitis (NASH) is a disease closely associated with obesity 
and diabetes. A prevalence of type 2 diabetes and a high body mass index in cryptogenic 
cirrhosis may imply that obesity leads to cirrhosis. Here, we examined the effects of an 
extract of Ecklonia cava, a brown algae, on the activation of high glucose-induced hepatic 
stellate cells (HSCs), key players in hepatic fibrosis. Isolated HSCs were incubated with or 
without a high glucose concentration. Ecklonia cava extract (ECE) was added to the culture 
simultaneously with the high glucose. Treatment with high glucose stimulated expression of 
type I collagen and α-smooth muscle actin, which are markers of activation in HSCs, in a 
dose-dependent manner. The activation of high glucose-treated HSCs was suppressed by the 
ECE. An increase in the formation of intracellular reactive oxygen species (ROS) and a 
decrease in intracellular glutathione levels were observed soon after treatment with high 
glucose, and these changes were suppressed by the simultaneous addition of ECE. High 
glucose levels stimulated the secretion of bioactive transforming growth factor-β (TGF-β) 
from the cells, and the stimulation was also suppressed by treating the HSCs with ECE. 
These results suggest that the suppression of high glucose-induced HSC activation by ECE 
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is mediated through the inhibition of ROS and/or GSH and the downregulation of TGF-β 
secretion. ECE is useful for preventing the development of diabetic liver fibrosis.  
Keywords: type I collagen; Ecklonia cava; reactive oxygen species; transforming growth 
factor-β; high glucose; hepatic stellate cells 
 
1. Introduction  
A prevalence of type 2 diabetes mellitus and a high body mass index in cryptogenic cirrhosis may 
imply that obesity leads to cirrhosis [1,2]. In addition, hyperglycemia and hyperinsulinemia may 
accelerate liver fibrosis and cirrhosis [3]. It has also been reported that advanced glycation end 
products (the final reaction products of proteins with sugars) induce reactive oxygen species (ROS) 
generation and intensify the proliferation and activation of hepatic stellate cells (HSCs), key players in 
hepatic fibrosis [4]. 
It has been shown that an induction of collagen gene expression in renal fibroblasts by high glucose 
levels is one of the mechanisms of diabetic nephropathy. Moreover, hyperglycemia has been shown to 
be functionally related to fibrogenesis in a model of diabetic nephropathy in which the progressive 
accumulation of extracellular matrix (ECM) components was observed in the glomerular mesangium 
and tubulointerstitium [5]. HSCs are a major source of ECM, and during fibrogenesis, they undergo an 
activation process that is characterized by increased proliferation and collagen synthesis. Therefore, it 
is important to establish an in vitro model of diabetic fibrosis with HSCs to clarify the mechanism of 
high glucose-induced fibrogenesis in nonalcoholic steatohepatitis (NASH). In this regard, Sugimoto et al. 
have shown that high glucose concentrations (450 and 600 mg/dL) stimulate HSCs to proliferate and 
express type I collagen to a greater extent than normal serum concentrations of glucose (100 mg/dL) and 
that high glucose concentrations induce the growth of HSCs via MAP kinase pathways, which are 
activated by ROS produced by the NADPH oxidase system under the regulation of protein kinase C [6]. 
It is now widely accepted that ROS play a critical role in the development of hepatic fibrosis by 
increasing the deposition of ECM [7,8]. Various studies have demonstrated that an increase in ROS by 
a hepatic injury induces proinflammatory cytokines, such as tumor necrosis factor-α, transforming 
growth factor-β (TGF-β), interleukin-1β, and interleukin-6, which are critical for HSC activation   
and perpetuation [5]. Among these, TGF-β is thought to be an important cytokine in regulating the 
production, degradation, and accumulation of ECM proteins.  
Ecklonia cava, which is abundantly produced on Juju Island in Korea, is popular in Japan and 
Korea, where this valuable brown algae is utilized as an ingredient for food, animal feed, fertilizers and 
medicine. Polyphenolic compounds are in the blown algae are called as phlorotannins. Phlorotannin 
components, which are oligomeric polyphenols composed of phloroglucinol units, are responsible for 
the pharmacological activities of Ecklonia cava, and phlorotannins, such as eckol (a closed-chain trimer 
of phloroglucinol), 6,6'-bieckol (a hexamer) and phlorofucofuroeckol (a pentamer), were identified in the 
Ecklonia cava species [9]. Many researchers have reported that the Ecklonia species exhibits radical 
scavenging [10,11], anti-plasmin inhibiting [12,13], anti-mutagenic [14], bactericidal [15], HIV-1 
reverse transcriptase and protease inhibition [16] and tyrosinase inhibitory [17] activities. It has also Mar. Drugs 2011, 9                                                
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been reported that the amount of total polyphenolic compounds in Ecklonia cava is greater than that in 
other brown seaweeds [18].  
In the present study, we examined the influence of Ecklonia cava extract (ECE) on high   
glucose-induced HSC activation and found that ECE suppressed the activation by decreasing the 
production of ROS and TGF-β
2. Results 
2.1. Changes in α-Smooth Muscle Actin Expression and Cell Proliferation after Hepatic Stellate Cell 
(HSC) Isolation 
It is known that HSCs spontaneously demonstrate an activated phenotype and begin to proliferate after 
being plated. To ascertain when the phenotypical activation and proliferation of the HSCs are induced in 
our experimental conditions, we cultured HSCs for 13 days. The cell number was significantly increased 
after 7 days of culturing (Table 1). Similarly, the expression of α-smooth muscle actin (α-SMA), the most 
reliable marker for HSC activation, was observed in control HSCs after 7 days (Figure 1). The staining 
for α-SMA, using a computer with NIH image, were 15.7 ± 9.1, 16.1 ± 2.9, 22.4 ± 8.7, 37.6 ± 9.1 and 
53.5 ± 6.7 pixels at 3, 5, 7, 9, 11 and 13 days after HSC isolation, respectively. Based on cell 
proliferation and the expression of α-SMA, HSCs that were cultured for 5 days were quiescent. 
Table 1. Time-dependent effect of HSC proliferation. 
Days after HSC isolation  Cell number (cells/field) 
3  40.2 ± 8.2 
a 
5  56.3 ± 7.1 
a 
7  77.5 ± 7.8 
b 
9  119.9 ± 20.9 
c 
11  151.8 ± 18.8 
d 
13  166.5 ± 13.9 
d 
HSCs cultured for 3, 5, 7, 9, 11 or 13 days were counterstained with hematoxylin. Data are 
presented as means ± SD. Means with different superscript letters are significantly different   
(p < 0.01). Five independent experiments were performed.  
Figure 1. Time-dependent effect of α-SMA expression in HSCs. HSCs were cultured for 3, 
5, 7, 9, 11 or 13 days. At the end of the incubation, cells were fixed with 4% 
paraformaldehyde overnight at 4 °C. An anti-α-SMA monoclonal antibody was used as the 
primary antibody. HSCs were cultured for (a) 3 days; (b) 5 days; (c) 7 days; (d) 9 days or 
(e) 13 days. Scale bars, 20 μm. 
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Figure 1. Cont. 
 
2.2. Effect of ECE on High Glucose-Induced HSC Activation 
In our previous study, we found that high glucose levels induced the activation of quiescent HSCs 
that were cultured for 5 days. To investigate the effect of ECE on high glucose-induced HSC 
activation, we examined the effect of ECE on the high glucose-induced increase in the expression of 
type I collagen in HSCs. HSCs were incubated for 24 h with 400 mg/dL glucose and various 
concentrations of ECE. As shown in Figure 2, treatment with ECE suppressed the high   
glucose-induced increase in the expression of type I collagen in HSCs. The staining for type I collagen, 
using a computer with NIH image, were 10.6 ± 3.8, 45.7 ± 5.7, 24.4 ± 7.1, 13.4 ± 3.4 and 14.9 ± 8.1 pixels, 
in the cells for control (100 mg/dL glucose), 400 mg/dL glucose, 400 mg/dL glucose plus 6.25 μg/mL 
ECE, 400 mg/dL glucose plus 12.5 μg/mL ECE and 400 mg/dL glucose plus 25 μg/mL ECE, 
respectively. The most effective concentration by immunostaining was found to be 12.5 µg/mL ECE, 
and this concentration was used for the following experiments. To quantitatively detect the expression 
of type I collagen, we measured the levels of intracellular type I collagen by Western blot analysis and 
showed that treatment of HSCs with 12.5 μg/mL ECE for 24 h markedly suppressed the high   
glucose-induced increase in the expression of type I collagen (Figure 3). 
Figure 2. The effect of ECE on the high glucose-induced increase in the expression of type I 
collagen in HSCs. HSCs were incubated for 24 h with 400 mg/dL glucose. ECE (6.25, 12.5 
or 25 μg/mL) was added simultaneously with the glucose. At the end of the incubation, 
cells were fixed with 4% paraformaldehyde overnight at 4 °C. An anti-type I collagen 
polyclonal antibody was used as the primary antibody. (a) Control (100 mg/dL glucose); 
(b) 400 mg/dL glucose; (c) 400 mg/dL glucose plus 6.25 μg/mL ECE; (d) 400 mg/dL glucose 
plus 12.5 μg/mL ECE; and (e) 400 mg/dL glucose plus 25 μg/mL ECE. Scale bars, 20 μm. 
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Figure 2. Cont. 
 
Figure 3. The effect of ECE on the high glucose-induced increase in the expression of  
α-SMA in HSCs. HSCs were treated with 400 mg/dL glucose for 24 h. ECE (12.5 μg/mL) 
was added simultaneously with the glucose. Cell lysis and western blot analysis were 
performed as described in the Materials and Methods section. Data shown are representative 
of three independent experiments. 
 
2.3. Effect of ECE on the Proliferation of High Glucose-Treated HSCs 
To investigate the effect of ECE on high glucose-induced HSC activation, we also examined the 
effect of ECE on the high glucose-induced increase in the proliferation of HSCs. HSCs were incubated 
for 24 h with 400 mg/dL glucose and 12.5 μg/mL ECE. As shown in Figure 4, treatment with ECE 
reduced the high glucose-induced cell proliferation to the level of the control cells. Mar. Drugs 2011, 9                                                
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Figure 4. The effect of Ecklonia cava extract (ECE) on the proliferation of high   
glucose-treated HSCs. HSCs were treated with 400 mg/dL glucose for 24 h. ECE   
(12.5 μg/mL) was added simultaneously with the glucose. Cell viability was measured 
using an MTT assay. Each value is the mean ± SD. Values without a common letter are 
significantly different (p < 0.01). Five independent experiments were performed. 
 
2.4. Effect of ECE on Intracellular ROS Levels of High Glucose-Treated HSCs 
To investigate the relationship between high glucose-induced HSC activation and ROS   
formation, we measured the level of intracellular ROS using 2',7'-dichlorodihydrofluorescein diacetate  
(DCFH-DA), which is converted to the highly fluorescent DCF in the presence of intracellular ROS. 
The increase in ROS formation in high glucose-treated HSCs was inhibited by the addition of ECE 
(Figure 5).  
Figure 5. The effect of ECE on the intracellular ROS levels of high glucose-treated HSCs. 
HSCs were incubated for 2 h with 400 mg/dL glucose. ECE (12.5 μg/mL) was added 
simultaneously with the glucose. During the last 30 minutes of culture, the cells were 
incubated with 2.4 mM DCFH-DA. (a) Control (100 mg/dL glucose); (b) 400 mg/dL glucose; 
and (c) 400 mg/dL glucose plus 12.5 μg/mL ECE. The data shown are representative of 
three independent experiments. Scale bars, 20 μm. 
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2.5. Effect of ECE on the Intracellular MDA Levels of Glucose-Treated HSCs 
We examined the effect of ECE on the high glucose-induced increase of intracellular lipid 
peroxidation using a TBARS assay. HSCs were incubated for 6 h with 400 mg/dL glucose and   
12.5 μg/mL of ECE. The ECE treatment returned the intracellular MDA level to the level of the 
control cells (Figure 6). 
Figure 6. Effect of ECE on MDA levels in high glucose-treated HSCs. HSCs were treated 
with 400 mg/dL glucose for 6 h. ECE (12.5 μg/mL) was added simultaneously with the 
glucose. After incubation, the intracellular MDA levels were assayed using a TBARS 
assay, as described in the Materials and Methods section. Data are presented as means ± SD. 
Values without a common letter are significantly different (p < 0.01). Five independent 
experiments were performed. 
 
2.6. Effect of ECE on the Intracellular GSH Levels of High Glucose-Treated HSCs 
To investigate the relationship between intracellular GSH levels and high glucose-induced HSC 
activation, we measured the intracellular GSH levels in HSCs using HPLC. As shown in Figure 7, the 
levels of intracellular GSH 2 h after a high glucose treatment were lower than those of the control 
cells. However, ECE not only reversed the decrease in GSH but also induced higher GSH levels than 
those in control cells. 
2.7. Effect of ECE on Bioactive TGF-β1 in High Glucose-Treated HSCs 
TGF-β1 is a potent profibrogenic signaling factor that triggers the expression, accumulation and 
deposition of collagen [19,20]. Therefore, we measured the levels of TGF-β1 in the cell culture 
medium using a Quantikine TGF-β1 ELISA kit (R&D Systems). As shown in Figure 8, a high glucose 
concentration (400 mg/dL) stimulated the cells to secrete bioactive TGF-β1, and the stimulation was 
suppressed upon treatment of the HSCs with ECE. Mar. Drugs 2011, 9                                                
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Figure 7. The effect of ECE on the intracellular GSH levels of high glucose-treated   
HSCs. HSCs were treated with 400 mg/dL glucose for 2 h. ECE (12.5 μg/mL) was added 
simultaneously with the glucose. After the incubation, the intracellular GSH levels were 
assayed by HPLC, as described in the Materials and Methods section. Data are presented as 
means ± SD. Values without a common letter are significantly different (p < 0.01).   
Five independent experiments were performed. 
 
Figure 8. The effect of ECE on the secretion of bioactive TGF-β1 by high glucose-treated 
HSCs. HSCs were treated with 400 mg/dL glucose for 24 h. ECE (12.5 μg/mL) was added 
simultaneously with the glucose. After the incubation, the levels of secreted bioactive 
TGF-β1 were determined by an ELISA, as described in the Materials and Methods section. 
Data are presented as means ± SD. Values without a common letter are significantly 
different (p < 0.01). Five independent experiments were performed. 
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3. Discussion  
The significant finding of this study is that ECE suppressed the high glucose-induced HSC activation 
in vitro. To the best of our knowledge, the involvement of ROS and/or GSH inhibition and the 
downregulation of TGF-β secretion by ECE are novel.  
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that ranges in severity 
from steatosis to cirrhosis. The prevalence of NAFLD has been estimated to be between 20% and 30% 
in the general population, but this value is much higher (~70–80%) in patients with type 2 diabetes 
mellitus, who are also at a higher risk of developing advanced fibrosis and cirrhosis [21]. In addition, 
Picardi et al. showed that hyperglycemia and hyperinsulinemia might accelerate liver fibrosis and 
cirrhosis [3]. Nan et al. have shown that rosiglitazone, which is used as a clinical treatment for insulin 
resistance in patients with type 2 diabetes mellitus, ameliorated hepatic fibrosis by activating PPARγ, 
which can inhibit HSC activation and suppress the expression of TGF-β1 and connective tissue growth 
factor. When the drug was given to mice fed a high-fat, methionine-choline deficient diet for 8 weeks 
to induce hepatic fibrosis, it decreased the severity of the liver disease [22]. Currently, no agents or 
natural products have been confirmed as preventing the activation of HSCs in diabetic liver fibrosis. In 
this study, we examined the effect of ECE on high glucose-induced HSC activation. 
In cirrhotic livers, HSCs are responsible for the increased production and deposition of the   
ECM. Activation of HSCs in vivo and in vitro includes the increased expression of type I collagen, the 
expression of cytoskeleton markers such as α-SMA, and increased proliferation [23,24]. Sugimoto et al. 
have shown that high glucose concentrations stimulated the cell proliferation of HSCs and the production 
of type I collagen by HSCs. However, the mechanisms of hepatic fibrosis, which is promoted by high 
glucose concentrations, are not well defined [6]. We confirmed that high glucose concentrations (400 and 
600 mg/dL) stimulated cell proliferation and type I collagen expression by HSCs to a greater extent 
than normal serum glucose concentrations (100 mg/dL) (data not shown). In this study, we showed that 
the secretion of TGF-β1 and the formation of ROS were stimulated and that the intracellular GSH 
levels were decreased in HSCs at high glucose concentrations. 
ROS has been thought to be an important trigger for HSC activation and for promoting the 
expressions of fibrogenic molecules such as α-SMA, TGF-β, and type I collagen. TGF-β plays a 
critical role in the development of hepatic fibrosis through its stimulating effect on matrix protein 
generation and its inhibitory effect on matrix protein removal [20,25]. The expression of TGF-β is 
increased in various models of human liver disease, which range from cholestatic liver disease and 
hepatitis to liver cirrhosis [26–28]. Recent studies have demonstrated that TGF-β is a potent inducer of 
both the α-1(I) and α-2(I) collagen genes. In addition, a TGF-β-responsive element has been mapped to 
the promoter region of the α-2(I) collagen gene [29]. The finding of this study that a high glucose 
concentration intensified the generation of ROS, which was then followed by HSC activation in 
association with enhanced TGF-β secretion, adds new information to the mechanism of liver 
fibrogenesis. The increases in ROS formation and TGF-β secretion in high glucose-induced HSCs 
were inhibited by the addition of ECE.  
The levels of ROS are modulated not only by the amount of ROS produced but also by antioxidant 
levels. The production of ROS leads to antioxidant depletion, thereby amplifying the biological 
consequences of oxidant stress. GSH has been implicated in various cellular events, such as the Mar. Drugs 2011, 9                                                
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inflammatory response, regulation of cell proliferation, modulation of redox-regulated signal 
transduction and remodeling of the extracellular matrix [30]. In this experiment, we found that the 
level of intracellular GSH was decreased after treatment with high glucose when compared to that of 
the control cells. The decrease in GSH levels in high glucose-treated HSCs was suppressed by 
treatment with ECE. ECE not only reversed the decrease in GSH but also induced greater GSH levels 
than those in control cells. Kang et al. have shown that phloroglucinol, a phlorotannin compound 
isolated from Ecklonia cava, restored the level of GSH and the protein expression of the catalytically 
active subunit glutamate-cysteine ligase, which is a rate-limiting enzyme in GSH biosynthesis, in cells 
exposed to γ-rays [31]. 
Polyphenolic compounds are abundant in seaweeds, and the polyphenolic compounds that are 
contained in brown algae are called phlorotannins. Ecklonia cava, which is a brown algae, has various 
phlorotannins that are highly hydrophilic compounds [32]. Ahn et al. investigated the potential 
antioxidant activities of three phlorotannins (phloroglucinol, eckol and dieckol) purified from Ecklonia 
cava and indicated that those phlorotannins showed notable radical scavenging activities; in particular, 
eckol had a superior scavenging activity for free radicals and inhibited DNA damage [33].  
These studies suggested that ECE is useful for preventing the development of diabetic liver   
fibrosis. However, further studies are required to ascertain whether ECE may be beneficial in high 
glucose-induced or NASH-associated hepatic fibrosis in animals. 
4. Materials and Methods 
4.1. Materials 
Nycodenz was obtained from Nycomed Pharma AS (Oslo, Norway). Pronase E was purchased  
from Merck (Darmstadt, Germany). Deoxyribonuclease I was obtained from Roche LTD (Basel, 
Switzerland). Collagenase was purchased from Wako Pure Chemical Co., Ltd. (Osaka, Japan). DMEM 
was obtained from Nissui Pharmaceutical Co. Ltd. (Tokyo, Japan). Fetal bovine serum (FBS) was 
purchased from Nichirei Biosciences, Inc. (Tokyo, Japan). Monoclonal mouse anti-human smooth 
muscle actin antibody 1A4, biotinylated goat anti-mouse immunoglobulin and biotinylated goat   
anti-rabbit immunoglobulin and horseradish peroxidase-labeled streptavidin-biotin complex were 
obtained from DAKO A/S (Glostrup, Denmark). Rabbit anti-rat collagen type I polyclonal antibody 
was obtained from Chemicon International, Inc. (Temecula, CA, USA). The Quantikine TGF-β1 
ELISA kit was obtained from R&D Systems, Inc. (Minneapolis, Minnesota, MN, USA). Other 
chemicals used in this study were special-grade commercial products purchased from WAKO Pure 
Chemical Co., Ltd. (Osaka, Japan). 
4.2. Ecklonia cava Extract 
A commercially available polyphenol extract from Ecklonia cava (Seapolynol, Livechem Inc, Jeju, 
Korea) was used. The total polyphenol content of the Ecklonia cava extract was 99.4%, as measured 
by the Folin-Ciocalteu reagent using phloroglucinol as a standard. Notable compounds in the Ecklonia 
cava extract that were identified by HPLC were dieckol (8.2%), 8,8'-bieckol (2.8%), 2-O-(2,4,6-
trihydroxyphenyl)-6,6'-bieckol (2.1%), 6,6'-bieckol (1.5%), phlorofurofucoeckol-A (1.4%),   Mar. Drugs 2011, 9                                                
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eckol (0.6%), 2-phloroeckol (0.4%), 7-phloroeckol (0.4%) and phlorotannin A (0.4%) (Waters, 
column: CAPCELL PAK ODS column (4.6 × 250 mm); eluent: 30% aqueous MeOH;   
flow rate: 0.8 mL/min) [11]. 
4.3. Animals  
Male Wistar rats, which weighed 300–350 g, were purchased from Japan SLC Inc. (Shizuoka, 
Japan) and housed at constant temperature with free access to water and standard rat chow (Labo MR 
stock; Japan SLC, Inc., Shizuoka, Japan). Animal experiments followed our institution’s criteria for 
the care and use of laboratory animals in research, which were in accordance with the guidelines for 
animal experimentation at Osaka City University. 
4.4. Isolation and Culturing of HSCs 
HSCs were isolated from male Wistar rats as previously described [34]. HSCs were identified by 
their typical star-like configuration and a vitamin A autofluorescence. The purity was always higher 
than 95%. In the experiments to ascertain changes in α-smooth muscle actin α-SMA) expression and 
cell proliferation after HSC isolation, the cells were plated at 5 × 10
5 cells/mL on uncoated culture 
dishes in 1.5 mL of DMEM containing 10% FBS and supplemented with antibiotics (10
5 U/L of 
penicillin G and 500 mg/L of streptomycin) until 13 days. The medium was changed to fresh DMEM 
containing 10% FBS every 2 days. For the experiments on high glucose-induced HSC activation, the 
cells were plated at 5 × 10
5 cells/mL on uncoated culture dishes in 1.5 mL of DMEM containing 10% FBS 
and supplemented with antibiotics for 2 days and then cultured in fresh medium without serum for 24 h. 
After a pre-incubation, the cells were cultured in DMEM with different concentrations of glucose. 
4.5. Immunohistochemistry 
At the end of the incubation, the HSCs were fixed with 4% paraformaldehyde overnight at 4 °C. We 
used either an anti-α-SMA monoclonal antibody (1:100 dilution) or an anti-type I collagen polyclonal 
antibody (1:200 dilution) as the primary antibody. The samples were sequentially incubated with 0.3% 
hydrogen peroxide, followed by normal goat serum, then with the primary antibody for 1 h at room 
temperature, and afterwards with the biotinylated anti-mouse or anti-rabbit goat immunoglobulins   
for 30 min. This was then followed by an incubation with the horseradish peroxidase-labeled 
streptavidin-biotin complex for 30 min. For the peroxidase reaction, 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) with a nickel chloride color modification was incubated for 5 min until the 
desired color intensity had developed. Quantification of the intensity of α-SMA and type I collagen 
expression was analyzed using a computer with the NIH image version 1.62 (National Institutes of 
Health, Bethesda, MD, USA).  
4.6. Western Blot Analysis of α-SMA 
Cells were harvested, washed twice with cold PBS and then dissolved with lysis buffer X (10 mM 
HEPES (pH 7.6), 10 mM KCl, 0.1 mM EDTA, 0.5% Nonidet P40, 1 mM dithiothreitol, 0.5 mM 
phenylmethylsulfonyl fluoride). After freezing and thawing twice with liquid nitrogen, the cells were Mar. Drugs 2011, 9                                                
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sonicated and centrifuged at 800 × g for 10 min at 4 °C. The supernatant was collected for the cytosolic 
fraction. The precipitant was dissolved with lysis buffer Y (150 mM NaCl, 50 mM tris (pH 7.2),   
1 mM EDTA, 1% Nonidet P40, 10 µg/mL leupeptin, 10 µg/mL pepstatin A and 100 µg/mL 
phenylmethylsulfonyl fluoride) for 30 min. Finally, the solution was sonicated and centrifuged at   
2000 × g for 20 min at 4 °C, and the supernatant was collected for the nuclear fraction. Equal amounts 
of protein were loaded into the lanes of 10% SDS-PAGE gels, and the separated proteins were blotted 
to 0.45 µm polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia Biotech, Inc., 
Uppsala, Sweden). After blocking overnight with 0.1% Tween-20 and 5% non-fat dry milk in TBS, the 
membrane was incubated with an anti-α-SMA antibody for 1 h at room temperature. After washing, 
the membrane was re-incubated with biotinylated anti-mouse goat immunoglobulin (diluted 1:1000) 
for 1 h at room temperature. Next, the membrane was washed several times and then incubated with 
horseradish peroxidase-coupled streptavidin (diluted 1:200) for 1 h at room temperature. After several 
washing steps, the color reaction was developed with DAB. Densitometric analysis of the protein 
bands was performed using the software Scion Image (Scion Corporation, Frederick, MD, USA).  
4.7. Determination of Intracellular GSH Levels  
The intracellular GSH levels were determined according to the method of Sack et al. [35]. Cells 
were collected with Tris-HCl buffer (25 mM Tris adjusted to pH 7.5 with HCl). After sonication and 
centrifugation, the supernatant was used for an HPLC assay. For assaying GSH, 300 µL of supernatant 
was mixed with 300 µL of borate buffer (0.56 N boric acid adjusted to pH 10.4 with NaOH) and 50 µL 
of an OPA solution (10 mg/mL OPA in 10% methanol). GSH was separated on an ODS-II column  
(4.6 × 150 mm; particle size 5 µm; Shimadzu Techno-Research, Kyoto, Japan) using solvents A   
(30 mM sodium acetate adjusted to pH 6.0 with acetic acid) and B (92.3% methanol/7.7% acetonitrile, 
v/v). The sample was eluted with 96% solvent A and 4% solvent B and then with a programmed 
solvent gradient using a linear gradient curve. The gradient changed from 4 to 10% of solvent B from 0 
to 5 min, from 10 to 14.9% of solvent B from 5 to 15 min, and from 14.9 to 4% of solvent B from  
20 to 21 min at a flow rate of 0.45 mL/min. The fluorescence of the eluted fractions was measured 
using an RF1520 fluorescence monitor at excitation and emission wavelengths of 230 and 445 nm, 
respectively, to assay the GSH levels (JASCO Corporation, Tokyo, Japan).  
4.8. MTT Assay  
The MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide] assay, an index of cell 
viability and growth, is based on the ability of viable cells to reduce a yellow water-soluble dye to a 
dark-blue insoluble formazan product. After 24 h of culture, the cells were incubated with the MTT 
solution for 2 h. The cells showing an MTT reaction were quantified at 600 nm using a multilabel 
counter (Wallac 1420 ARVOsx, Perkin Elmer Inc., Waltham, MA, USA). Cell survival was estimated 
as a percentage of the value of the untreated controls. Mar. Drugs 2011, 9                                                
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4.9. Intracellular ROS Formation 
A relatively specific probe for the presence of hydrogen peroxide, 2',7'-dichlorodihydrofluorescein 
diacetate (DCFH-DA), was used to analyze the intracellular ROS formation [36,37]. Cells were 
incubated with 2.4 mM DCFH-DA (5 µL) for the last 30 min of the glucose treatment. Cells were 
washed with PBS twice and resuspended in Hank’s solution. The fluorescence intensities were 
measured using a multilabel counter (Wallac 1420 ARVOsx, Perkin Elmer Inc.) with an excitation 
wavelength of 485 nm and an emission wavelength of 535 nm. The amount of intracellular ROS  
was calculated from a standard curve derived from 2',7'-dichlorofluorescein (DCF). The protein 
concentration was measured using the Bradford method [38]. For visualization of the intracellular 
fluorescence, the cells were observed with an FSX100 Bio Imaging Navigator, which is an all-in-one 
fluorescence imaging system (Olympus Corporation, Tokyo, Japan). 
4.10. Evaluation of Intracellular Lipid Peroxidation 
Lipid peroxidation was assessed by determining the rate of production of thiobarbituric acid   
(TBA)-reactive components, which mainly detect malonaldehyde (MDA) [39]. After incubating   
for 6 h, the HSCs were collected and resuspended in 500 µL of Hank’s solution. After freezing and 
thawing, the 250 µL suspension was diluted to 500 µL with distilled water and then mixed with 15 µL 
of 50 mM butylated hydroxytoluene (BHT) and 1 mL of the thiobarbituric acid (TBA) solution. The 
mixtures were heated at 95 °C for 15 min. The fluorescence intensities were measured using a 
multilabel counter (Wallac 1420ArVOsx, Perkin Elmer Inc.) with an excitation wavelength of 485 nm 
and an emission wavelength of 535 nm. Tetramethoxypropane was used for a standard, and the results 
are expressed as nmol equivalents of MDA. 
4.11. Measurement of Activated TGF-β1 Concentrations 
TGF-β1 was analyzed using a Quantikine TGF-β1 ELISA kit (R&D Systems, Inc.) according to the 
manufacturer’s instructions. The assay employs the quantitative sandwich enzyme immunoassay 
technique. The intensity of the color was measured at 450 nm by a multilabel counter (Wallac 1420 
ARVOsx, Perkin Elmer Inc.). The concentrations of the total TGF-β1 was calculated from a standard 
curve derived from various defined concentrations of recombinant TGF-β1.  
4.12. Statistical Analysis 
Results are presented as the means ± S.D. Statistical comparisons were performed between groups 
by a one-way analysis of variance and a post-hoc multiple comparison using a Tukey’s test. A p-value 
less than 0.05 was considered significant. 
5. Conclusions  
In conclusion, the results obtained in this study indicate that high glucose concentrations trigger an 
increase in collagen synthesis by HSCs, and this may be related to or involved in an increased 
formation of ROS, a depletion of the intracellular GSH content and an increase in the expression of Mar. Drugs 2011, 9                                                
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TGF-β1. The suppression of the high glucose-induced HSC activation by ECE was mediated by an 
inhibition of the ROS and/or GSH signal and a downregulation of TGF-β1 secretion. ECE may be 
useful in preventing the development of diabetic liver cirrhosis. 
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